News

Merck Serono, a unit of German pharmaceutical manufacturer Merck, has signed a licensing agreement with US-based biotechnology firm Threshold Pharmaceuticals for the development and commercialisation of TH-302. TH-302 is Threshold's small molecule hypoxia-targeted drug, designed...

A newly proposed cost-cutting rule implemented into the US Medicaid programme could save the country up to $17.7bn over five years, say US health officials. The proposed rule on prescription drugs purchased through the state...

Shire has signed a collaboration and license agreement with Sangamo Bioscience to develop therapeutics for hemophilia and other monogenic diseases using Sangamo's zinc finger DNA-binding protein (ZFP) technology. Under the collaboration agreement, Shire will...

NanoViricides has submitted a pre- Investigational New Drug (IND) briefing document of its anti-influenza drug candidate, FluCide to the US Food and Drug Administration (FDA). In a lethal influenza infection mouse model, FluCide has...

Orexo and Janssen Pharmaceuticals, formerly Ortho-McNeil-Janssen Pharmaceuticals, and Janssen Pharmaceutica, have terminated their research collaboration and license agreement regarding the OX-CLI and OX-ESI programs. A third, undisclosed Janssen program was also terminated. Each party has...

Precision BioSciences has received US patent which covers claims related to methods of cleaving a target DNA site in a cell using an engineered meganuclease. These methods are broadly utilized as a part of Precision's...

Vanda Pharmaceuticals' tasimelteon has shown the ability to reset the body clock and to align it to a constant 24-hour day in patients suffering from Non-24-Hour Sleep-Wake Disorder (Non-24-Hour Disorder). Tasimelteon is a circadian...